FDA rejection and regulatory status Development timeline: 2000s: Developed for Parkinson's/Alzheimer's 2008: Phase 2 obesity trials (successful) 2010: Phase 3 trials initiated 2010: Development halted due to safety concerns 2012: FDA rejected obesity indication Present: No approved indication anywhere Why FDA rejected: Cardiovascular safety concerns primary reason Increased heart rate and blood pressure Risk-benefit ratio unfavorable Safer alternatives available ( GLP-1 agonists ) Development company abandoned pursuit No current path to approval Regulatory status by country: Current legal classification: Not a controlled substance (not scheduled) Not approved for any human use Sold as "research chemical" only "Not for human consumption" labels Legal gray area (enforcement rare) See are peptides legal guide at SeekPeptides

[19] Implications of proton-wire-mediated asymmetry for catalysis A consequence of this mechanism is that, as the catalytic cycles proceed, the two active sites remain out of phase with each other
Ability to Restore Intracellular Calcium PTER is able to increase the capacity of intracellular calcium restoration by reducing recovery time after cell depolarization (Joseph et al., 2008)
Retrospective cohort study of adult RMS patients treated with KESIMPTA (n=576) or oral DMTs (n=576) (dimethyl fumarate, fingolimod, teriflunomide, cladribine, siponimod, ozanimod, diroximel fumarate, monomethyl fumarate, and ponesimod)
10.1123/ijsnem.2017-0267 189 ThorpeC
LRRK2 mutations (such as G2019S) promote mitochondrial fission in microglia by enhancing kinase activity, releasing mtROS and other factors to activate the NLRP3 inflammasome, exacerbating neuroinflammation in PD, and their regulation of mitochondrial dynamics has potential associations with ferroptosis (124)